ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "Acalabrutinb + BR and sotorasib + panitumumab"
Episode Synopsis
FDA approves two new treatment regimens:
1. Acalabrutinib + BR for untreated mantle cell lymphoma patients deemed ineligible for autologous HSCT
2. Sotorasib + panitumumab for KRAS-G12C mutated metastatic colorectal cancer (after chemotherapy, including oxaliplatin and irinotecan)
1. Acalabrutinib + BR for untreated mantle cell lymphoma patients deemed ineligible for autologous HSCT
2. Sotorasib + panitumumab for KRAS-G12C mutated metastatic colorectal cancer (after chemotherapy, including oxaliplatin and irinotecan)
More episodes of the podcast OncoPharm
Bladder Cancer Updates & SC Amivantamab
18/12/2025
ASH 2025
11/12/2025
DPYD Deficiency Testing
04/12/2025
Cornucopia of Autumn Updates
26/11/2025
PGYNone: Dandelion Effect
20/11/2025
PGY1 Pathway: Road Trip!
13/11/2025
PGY2 Pathway: A Planned City
06/11/2025
Tale from the Crypt: Belantamab Mafodotin
30/10/2025
ESMO 2025
23/10/2025
IL-2
16/10/2025
In God we trust